Your search returned 3 results.

Results
	1.	The importance of PK/PD data-key biological answers needed to evaluate the success of potential cancer therapeutics. [electronic resource] by Kumar, Rakesh Suttle, Benjamin Producer: 20120315 In: Molecular cancer therapeutics vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. [electronic resource] by Sarkozy, Clémentine Morschhauser, Franck Dubois, Sydney Molina, Thierry Michot, Jean Marie Cullières-Dartigues, Peggy Suttle, Benjamin Karlin, Lionel Le Gouill, Steven Picquenot, Jean-Michel Dubois, Romain Tilly, Hervé Herbaux, Charles Jardin, Fabrice Salles, Gilles Ribrag, Vincent Producer: 20210914 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. [electronic resource] by Italiano, Antoine Soria, Jean-Charles Toulmonde, Maud Michot, Jean-Marie Lucchesi, Carlo Varga, Andrea Coindre, Jean-Michel Blakemore, Stephen J Clawson, Alicia Suttle, Benjamin McDonald, Alice A Woodruff, Mark Ribich, Scott Hedrick, Eric Keilhack, Heike Thomson, Blythe Owa, Takashi Copeland, Robert A Ho, Peter T C Ribrag, Vincent Producer: 20190409 In: The Lancet. Oncology vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)